(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.34%) $82.73
(6.19%) $2.04
(0.00%) $2 347.10
(-0.24%) $27.47
(3.88%) $957.90
(-0.22%) $0.933
(-0.36%) $10.98
(-0.55%) $0.796
(1.67%) $93.40
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 8.94%
@ $49.09
Išleistas: 14 vas. 2024 @ 16:30
Grąža: 14.42%
Ankstesnis signalas: vas. 9 - 22:40
Ankstesnis signalas:
Grąža: -2.06 %
Live Chart Being Loaded With Signals
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support...
Stats | |
---|---|
Šios dienos apimtis | 705 592 |
Vidutinė apimtis | 671 158 |
Rinkos kapitalizacija | 3.03B |
EPS | $0 ( 2024-02-21 ) |
Kita pelno data | ( $0.450 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 175.53 |
ATR14 | $0.0660 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-30 | Bolton Stephanie | Buy | 7 744 | Ordinary Shares |
2024-03-30 | Bolton Stephanie | Buy | 10 746 | Stock Appreciation Rights |
2024-03-30 | Bolton Stephanie | Sell | 3 643 | Ordinary Shares |
2024-03-30 | Bolton Stephanie | Buy | 4 915 | Restricted Stock Units |
2024-03-30 | Bolton Stephanie | Buy | 4 915 | Performance Stock Units |
INSIDER POWER |
---|
50.90 |
Last 100 transactions |
Buy: 371 593 | Sell: 126 373 |
Tūris Koreliacija
LivaNova PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
IMPL | 0.932 |
AFYA | 0.931 |
JFU | 0.928 |
INVA | 0.925 |
EAR | 0.923 |
AVIR | 0.923 |
TUEM | 0.922 |
DTSS | 0.92 |
AZTA | 0.91 |
IMV | 0.91 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SERA | -0.945 |
NEO | -0.938 |
XLRN | -0.93 |
TA | -0.93 |
MLTX | -0.922 |
NTRA | -0.92 |
ZGNX | -0.91 |
XPON | -0.909 |
CPTA | -0.908 |
PAE | -0.908 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
LivaNova PLC Koreliacija - Valiuta/Žaliavos
LivaNova PLC Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $1.15B |
Bruto pelnas: | $785.45M (68.09 %) |
EPS: | $0.330 |
FY | 2023 |
Pajamos: | $1.15B |
Bruto pelnas: | $785.45M (68.09 %) |
EPS: | $0.330 |
FY | 2022 |
Pajamos: | $1.02B |
Bruto pelnas: | $707.20M (69.21 %) |
EPS: | $-1.610 |
FY | 2021 |
Pajamos: | $1.04B |
Bruto pelnas: | $705.99M (68.19 %) |
EPS: | $-2.68 |
Financial Reports:
No articles found.
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.